


Ask a doctor about a prescription for REVATIO 0.8 mg/mL INJECTABLE SOLUTION
Package Leaflet: Information for the Patient
Revatio 0.8 mg/ml Solution for Injection
sildenafil
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the pack
Revatio contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors (PDE5).
Revatio reduces blood pressure in the lungs by widening the blood vessels in the lungs. Revatio is used to treat high blood pressure in the blood vessels of the lungs (pulmonary arterial hypertension).
Revatio solution for injection is an alternative formulation of Revatio for patients who temporarily cannot take their Revatio tablets.
You should not be given Revatio
Warnings and precautions
Consult your doctor before starting to use Revatio if:
When PDE5 inhibitors, including sildenafil, are used to treat erectile dysfunction (ED), the following visual adverse effects have been reported with an unknown frequency: decreased or sudden, temporary, or permanent loss of vision in one or both eyes. If you experience a reduction or sudden loss of vision, stop taking Revatio and inform your doctor immediately(see also section 4).
Prolonged and sometimes painful erections have been reported in men taking sildenafil. If you have an erection that lasts for more than 4 hours, stop taking Revatio and consult your doctor immediately(see also section 4).
Special precautions in patients with kidney or liver problems
You should tell your doctor if you have kidney or liver problems, as a dose adjustment may be necessary.
Children and adolescents
Revatio should not be given to children and adolescents under 18 years.
Using Revatio with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Using Revatio with food and drink
You should not drink grapefruit juice when being treated with Revatio.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before being given this medicine. Revatio should not be used during pregnancy unless absolutely necessary.
Revatio should not be given to women of childbearing age unless adequate contraceptive methods are used.
Revatio passes into breast milk at very low levels and is not expected to harm your baby.
Driving and using machines
Revatio can cause dizziness and affect vision. You should know how you react to this medicine before driving vehicles or using machines.
Revatio is given as an intravenous injection and will always be given by a doctor or nurse. Your doctor will decide the duration of treatment and the amount of Revatio solution for injection you should receive daily and will monitor your response and disease. The recommended dose is 10 mg (corresponding to 12.5 ml) three times a day.
You should be given an intravenous injection of Revatio instead of Revatio tablets.
If you are given too much Revatio
If you are concerned that you have been given too much Revatio, tell your doctor or nurse immediately.
Taking more Revatio than you should can increase the risk of known side effects.
If you miss a dose of Revatio
As you will be given this medicine under close medical supervision, it is unlikely that you will miss a dose. However, tell your doctor or pharmacist if you think a dose has been missed. You should not be given a double dose to make up for missed doses.
If treatment with Revatio is stopped
Sudden stopping of treatment with Revatio can lead to worsening of your symptoms.
Your doctor may reduce the dose over a few days before stopping it completely.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Revatio can cause side effects, although not everybody gets them.
If you experience any of the following side effects, stop taking Revatio and tell your doctor immediately (see also section 2):
Adults
The side effects seen with Revatio intravenous were similar to those seen with Revatio tablets. In clinical trials, the most common side effects (may affect up to 1 in 10 patients) were facial flushing, headache, low blood pressure, and nausea.
In clinical trials, the most common side effects (may affect up to 1 in 10 patients) in patients with pulmonary arterial hypertension were facial flushing and nausea.
In clinical trials with Revatio tablets, the most common side effects (may affect more than 1 in 10 patients) were headache or facial flushing, indigestion, diarrhea, and pain in arms and legs.
Common side effects (may affect up to 1 in 10 patients) include: infection under the skin, flu-like symptoms, inflammation of the nasal passages, reduction in the number of red blood cells (anemia), fluid retention, difficulty sleeping, anxiety, migraine, tremor, tingling sensation, burning sensation, decreased sense of touch, bleeding in the back of the eye, changes in vision, blurred vision, and sensitivity to light, effects on color perception, eye irritation, red eyes, dizziness, bronchitis, nosebleeds, runny nose, cough, stuffy nose, stomach inflammation, gastroenteritis, heartburn, hemorrhoids, abdominal distension, dry mouth, hair loss, skin flushing, night sweats, muscle pain, back pain, and increased body temperature.
Uncommon side effects (may affect up to 1 in 100 patients) include: decreased visual acuity, double vision, abnormal sensation in the eye, penile bleeding, presence of blood in the semen and/or urine, and breast enlargement in men.
Rashes, decreased hearing, and low blood pressure have also been reported with an unknown frequency (frequency cannot be estimated from the available data).
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Monitoring System: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the vial and on the carton after EXP. The expiry date is the last day of the month shown.
Revatio does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Revatio contains
The active substance is sildenafil. Each ml of solution contains 0.8 mg of sildenafil (as citrate).
Each 20 ml vial contains 10 mg of sildenafil (as citrate).
The other ingredients are: glucose and water for injections.
What Revatio looks like and contents of the pack
Each pack of Revatio solution for injection contains a 20 ml clear glass vial, which is closed with a chlorobutyl rubber stopper and an aluminum seal.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Upjohn EESV, Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands.
Manufacturer:
Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, France.
You can obtain further information on this medicine from the local representative of the marketing authorization holder:
Spain
Viatris Pharmaceuticals, S.L.U.
Tel: +34 900 102 712
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites about rare diseases and orphan medicines.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for REVATIO 0.8 mg/mL INJECTABLE SOLUTION – subject to medical assessment and local rules.